The most important targeted treatment options in NSCLC include the epidermal growth factor receptor inhibitors (EGFRis), the vascular endothelial growth factor receptor inhibitors (VEGFRis), and the echinoderm microtubule–associated protein-like 4–anaplastic lymphoma kinase (EML4-ALK) fusion gene inhibitors.8 Other rare mutations are KRAS, ROS1, RET, and HER2. The gene discussed is ALK; the disease is non-small cell lung carcinoma.